Additional Blurbs Received

I received two additional blurbs for the cover of my upcoming scientific mystery-thriller “The Allston Variant.” Many thanks to Greg and Luke for their kind words:

The Allston Variant, Phil Temples’ frighteningly plausible new novel, enthralls with its breathtaking pace and complex heroine, scientist/undercover agent Carrie Bloomfield, while elucidating the latest advances in biotechnology. A smart, steamy thriller!  —Gregory Wolos, author of Women of Consequence and Turnpike

“Thrillers are my guilty pleasure, and The Allston Variant is the guiltiest of guilty pleasures.  Temples not only spins an excellent yarn, he can write!” —Luke Salisbury, author of The Answer Is Baseball and No Common War

Allston Variant Publication Date

From Gene Robinson from Moonshine Cove Publishing:

…We have placed your manuscript on our publication calendar in the next available slot and have assigned it the ISBN 9781945181573. As things stand now, it looks like publication will be near April 21, 2019. We should begin work on the manuscript about a month before that. In the meantime, as you suggest, it’s not too early to start thinking about what you’d like for a cover. We’d be pleased to hear your ideas and if you come across any interesting images, let us know.

It seems unbearably far in the future, but I’ve waited longer for some of my books to be published.

“Allston Variant” Picked Up By Moonshine Cove Publishing, LLC

Huzzah! I just signed a contract with a small publishing house, Moonshine Cove Publishing LLC., to produce the second installment of my Carrie Bloomfield Novel series called “The Allston Variant.” (The first in the series is “The Winship Affair”). I’m hoping the novel may be available for purchase on Amazon and elsewhere before year’s end.

Here’s a synopsis:

When scientists recover a deadly bacterium from the partially thawed permafrost of Alaska’s Northern Slope, the ancient pathogen kills the team members and decimates a small native village before mutating into a harmless version of itself. The U.S. Army moves in to collect samples for further study; the case is marked ‘Top Secret’ and closed. Eighteen years later, Cumulus Industries, a Boston biotechnology company, is tasked with developing a cure for the dangerous bacterium but the U.S. intelligence community soon suspects the company’s executive management of secretly engineering a biological weapon based on the bacterium. It plans to sell the weapon to a shadowy Middle East terrorist organization.

Suspicions are heightened when a Cumulus employee who is an undercover FBI informant mysteriously goes missing. The Bureau decides it must have another informant on the inside. It recruits the brilliant Boston scientist and entrepreneur Carrie Bloomfield who masquerades as Janice Silberman, a newly-hired researcher from Toronto. Silberman is befriended by an exotic and attractive fellow researcher, Argie Khorui. The two become best friends and lovers. But Khouri isn’t who she appears to be.

Bloomfield struggles to remain true to her mission while facing a daunting scientific challenge—the bioweapon is accidentally unleashed upon an unsuspecting Boston populace and Bloomfield must find a cure.